Drug Eluting Stent
9
0
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Stents Versus PAclitaxel Coated Balloons for Revascularization of CompleX and Small Coronary Vessels (SPARX) Trial
CREATE Trial, Prospective, Observational Study
CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)
Study on Absorbable Zinc Alloy Drug Eluting Coronary Stent System
Definite Stent Thrombosis in Comatose Out of Hospital Cardiac Arrest Survivors
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease
A Comparison Between FFR Guided and CAG Guided Treatment Using DEB in ISR of DES
Outcome of CHAllenging lesioNs and Patients Treated With Polymer Free Drug-CoatEd Stent
Angiographic and Intravascular Ultrasound (IVUS) Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals